key: cord-0917766-v2rq4yjm
authors: Stingeni, Luca; Francisci, Daniela; Bianchi, Leonardo; Hansel, Katharina; Tramontana, Marta; Di Candilo, Francesco; Mannarino, Massimo Raffaele; Pirro, Matteo
title: Severe adverse drug reaction in SARS‐CoV‐2 infection: AGEP induced by ceftriaxone and confirmed by patch test
date: 2021-04-23
journal: Contact Dermatitis
DOI: 10.1111/cod.13857
sha: 339b40c9f05fb18ec1a3b352879db9b751e382ad
doc_id: 917766
cord_uid: v2rq4yjm

nan

highlighted antimalarials, antivirals, and anti-inflammatory drugs, but not antibiotics. 1, 2 Only rare cases of drug-induced acute generalized exanthematous pustulosis (AGEP) due to hydroxychloroquine 3 and cephalosporins 4, 5 have been reported in patients with COVID-19, but in none of these cases were patch tests (PTs) performed.

During the first wave of COVID-19 in Italy, a 73-year-old woman with no history of drug allergies was admitted to our COVID-19 Unit with a 2-day history of fever (temperature 39 C), vomiting, and oxygen desaturation with breath sounds diminished bilaterally. Chest computed tomography revealed bilateral ground-glass opacities, and oxygen and intravenous ceftriaxone (2 g) was immediately started.

After a swab for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was positive, ceftriaxone was replaced with azithromycin (500 mg/day); hydroxychloroquine (400 mg/day), antiretroviral therapy with darunavir/cobicistat (800/150 mg/day), and enoxaparin (4000 UI/day) were added because of deterioration of the patient's clinical conditions. On day 5 azithromycin was discontinued.

Therapy was implemented with dexamethasone from day 8 to day 10 for progressive respiratory failure; on day 18, hydroxychloroquine and darunavir/cobicistat were also discontinued. On day 24, a high spiking fever (temperature 39.5 C) appeared and the patient received again intravenous ceftriaxone (2 g). One day later an extensive non-follicular pustular eruption on an erythematous base (60% of body surface area) appeared. Ceftriaxone was immediately discontinued and skin biopsy was According to the initial clinical picture and based on the EUROSCAR scoring system, definite AGEP with a final score of 9 (morphology 6: pustules, 2; erythema, 2; distribution, 2; and course 0: mucosal involvement, À2; acute onset, 0; fever, 1; neutrophils, 1; skin histology, 3) in a patient with COVID-19 was diagnosed.

Three months after complete healing, patch test with ceftriaxone sodium 5% and hydroxychloroquine 10%, both in pet., were The article has not been published previously and is not currently submitted elsewhere.

To the best of our knowledge, this is the first case of severe cutaneous ADR in a patient with COVID-19 patient confirmed by patch test.

The diagnostic value and safety of in vivo testing to investigate severe T cell-mediated hypersensitivities is still controversial. In fact, patch testing has been performed safely in AGEP, Drug Reaction with Eosinophilia and Systemic Symptoms, and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis, 7 whereas intradermal testing and provocation test in these severe ADRs are contraindicated. 8 We emphasize that in our patient patch testing with ceftriaxone showed a pustular reaction pattern, supporting the ability of the testing to reproduce the original ADR clinical pattern.

Chronology (fast elicitation in 1 day after reintroduction), elicitor, neutrophilia, positive pustular patch testing, and uncomplicated recovery of the patient pointed to an AGEP. As recently stated by the European Academy of Allergy Clinical Immunology position paper classification of cutaneous manifestations of drug hypersensitivity, 9 the large very superficial detachment observed in our patient resulted from confluent pustules resembling blisters.

The culprit drugs of AGEP are beta-lactam antibiotics, macrolides, diltiazem, terbinafine, and hydroxychloroquine. 9 In our patient, despite the large number of administered drugs, we performed a patch test with ceftriaxone for short latency time after its second administration and with hydroxychloroquine for its documented role in AGEP. 3, 9 Patch test confirmed ceftriaxone as the culprit, but unfortunately we could not perform ultra-structural studies on ceftriaxone positive patch-test biopsy to confirm the immunopathogenesis of AGEP, usually classified as a type IVd hypersensitivity reaction. 10 F I G U R E 1 (A) Extensive erythematous eruption with (B) flaccid superficial pustules resembling blisters and (C) superficial detachment. (D) Positive patch test (++) with a pustular reaction pattern to ceftriaxone (5% in pet., D4)

In conclusion, given the plethora of used drugs and the lack of approved therapies for patients with COVID-19, our report underscores the necessity to identify culprit drugs in ADRs in these patients and confirms the value and safety of patch tests.

All authors have no conflicts of interests to report. 

Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19: an EAACI position paper

Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: a guide for the dermatologist

Acute generalized exanthematous pustulosis with erythema multiforme-like lesions in a COVID-19 woman

Delayed presentation of acute generalized Exanthematous pustulosis following treatment with cefepime in a patient with COVID-19 without the use of Hydroxychloroquine

A case of cefditoren-induced acute generalized exanthematous pustulosis during COVID-19 pandemics. Severe cutaneous adverse reactions are an issue

Skin tests in the diagnosis of adverse drug reactions: a systematic review

A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions

Cutaneous drug hypersensitivity: developments and controversies

EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity

Drug reaction with eosinophilia and systemic symptoms from ceftriaxone confirmed by positive PT: an immunohistochemical study

Severe adverse drug reaction in SARS-CoV-2 infection: AGEP induced by ceftriaxone and confirmed by patch test